Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

Christos I Sinapis1,*, John G Routsias2,*, Angelos I Sinapis1,*, Dimitrios I Sinapis1,*, George D Agrogiannis3, Alkistis Pantopoulou1, Stamatis E Theocharis4, Stefanos Baltatzis5, Efstratios Patsouris3, Despoina Perrea11Laboratory for Experimental Surgery and Surgical Research 'N.S.Chris...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sinapis C, Routsias JG, Sinapis A, Sinapis D, Agrogiannis G, Pantopoulou A, Theocharis SE, Baltatzis S, Patsouris E, Perrea DN
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2011
Materias:
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/af53d795422f483f931ce5320837b88f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:af53d795422f483f931ce5320837b88f
record_format dspace
spelling oai:doaj.org-article:af53d795422f483f931ce5320837b88f2021-12-02T01:19:07ZPharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits1177-54671177-5483https://doaj.org/article/af53d795422f483f931ce5320837b88f2011-05-01T00:00:00Zhttp://www.dovepress.com/pharmacokinetics-of-intravitreal-bevacizumab-avastinreg-in-rabbits-a7517https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Christos I Sinapis1,*, John G Routsias2,*, Angelos I Sinapis1,*, Dimitrios I Sinapis1,*, George D Agrogiannis3, Alkistis Pantopoulou1, Stamatis E Theocharis4, Stefanos Baltatzis5, Efstratios Patsouris3, Despoina Perrea11Laboratory for Experimental Surgery and Surgical Research 'N.S.Christeas', 2Laboratory of Pathophysiology, 3Laboratory of Pathology, 4Laboratory of Forensic Medicine and Toxicology, 5Department of Ophthalmology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece *Contributed equally to the studyPurpose: To describe the pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits.Methods: The right eye of 20 rabbits was injected intravitreally with 1.25 mg/0.05 mL bevacizumab. Both eyes of four rabbits each time were enucleated at days 1, 3, 8, 15, and 29. Bevacizumab concentrations were measured in serum, aqueous humor, and vitreous.Results: Maximum vitreous (406.25 µg/mL) and aqueous humor (5.83 µg/mL) concentrations of bevacizumab in the right eye were measured at day 1. Serum bevacizumab concentration peaked at day 8 (0.413 µg/mL) and declined to 0.032 µg/mL at 4 weeks. Half-life values in right vitreous, right aqueous humor, and serum were 6.61, 6.51, and 5.87 days, respectively. Concentration of bevacizumab in the vitreous of the noninjected eye peaked at day 8 (0.335 ng/mL) and declined to 0.218 ng/mL at 4 weeks. In the aqueous humor of the noninjected eye, maximum concentration of bevacizumab was achieved at day 8 (1.6125 ng/mL) and declined (to 0.11 ng/mL) at 4 weeks.Conclusion: The vitreous half-life of 1.25 mg/0.05 mL intravitreal bevacizumab was 6.61 days in this rabbit model. Maximum concentrations of bevacizumab were reached at day 1 in both vitreous and aqueous humor of the right eye and at day 8 in the serum. Very low concentrations of bevacizumab were measured in the fellow noninjected eye.Keywords: bevacizumab, pharmacokinetics, rabbits, intravitrealSinapis CRoutsias JGSinapis ASinapis DAgrogiannis GPantopoulou ATheocharis SEBaltatzis SPatsouris EPerrea DNDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2011, Iss default, Pp 697-704 (2011)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Sinapis C
Routsias JG
Sinapis A
Sinapis D
Agrogiannis G
Pantopoulou A
Theocharis SE
Baltatzis S
Patsouris E
Perrea DN
Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits
description Christos I Sinapis1,*, John G Routsias2,*, Angelos I Sinapis1,*, Dimitrios I Sinapis1,*, George D Agrogiannis3, Alkistis Pantopoulou1, Stamatis E Theocharis4, Stefanos Baltatzis5, Efstratios Patsouris3, Despoina Perrea11Laboratory for Experimental Surgery and Surgical Research 'N.S.Christeas', 2Laboratory of Pathophysiology, 3Laboratory of Pathology, 4Laboratory of Forensic Medicine and Toxicology, 5Department of Ophthalmology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece *Contributed equally to the studyPurpose: To describe the pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits.Methods: The right eye of 20 rabbits was injected intravitreally with 1.25 mg/0.05 mL bevacizumab. Both eyes of four rabbits each time were enucleated at days 1, 3, 8, 15, and 29. Bevacizumab concentrations were measured in serum, aqueous humor, and vitreous.Results: Maximum vitreous (406.25 µg/mL) and aqueous humor (5.83 µg/mL) concentrations of bevacizumab in the right eye were measured at day 1. Serum bevacizumab concentration peaked at day 8 (0.413 µg/mL) and declined to 0.032 µg/mL at 4 weeks. Half-life values in right vitreous, right aqueous humor, and serum were 6.61, 6.51, and 5.87 days, respectively. Concentration of bevacizumab in the vitreous of the noninjected eye peaked at day 8 (0.335 ng/mL) and declined to 0.218 ng/mL at 4 weeks. In the aqueous humor of the noninjected eye, maximum concentration of bevacizumab was achieved at day 8 (1.6125 ng/mL) and declined (to 0.11 ng/mL) at 4 weeks.Conclusion: The vitreous half-life of 1.25 mg/0.05 mL intravitreal bevacizumab was 6.61 days in this rabbit model. Maximum concentrations of bevacizumab were reached at day 1 in both vitreous and aqueous humor of the right eye and at day 8 in the serum. Very low concentrations of bevacizumab were measured in the fellow noninjected eye.Keywords: bevacizumab, pharmacokinetics, rabbits, intravitreal
format article
author Sinapis C
Routsias JG
Sinapis A
Sinapis D
Agrogiannis G
Pantopoulou A
Theocharis SE
Baltatzis S
Patsouris E
Perrea DN
author_facet Sinapis C
Routsias JG
Sinapis A
Sinapis D
Agrogiannis G
Pantopoulou A
Theocharis SE
Baltatzis S
Patsouris E
Perrea DN
author_sort Sinapis C
title Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits
title_short Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits
title_full Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits
title_fullStr Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits
title_full_unstemmed Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits
title_sort pharmacokinetics of intravitreal bevacizumab (avastin®) in rabbits
publisher Dove Medical Press
publishDate 2011
url https://doaj.org/article/af53d795422f483f931ce5320837b88f
work_keys_str_mv AT sinapisc pharmacokineticsofintravitrealbevacizumabavastinampreginrabbits
AT routsiasjg pharmacokineticsofintravitrealbevacizumabavastinampreginrabbits
AT sinapisa pharmacokineticsofintravitrealbevacizumabavastinampreginrabbits
AT sinapisd pharmacokineticsofintravitrealbevacizumabavastinampreginrabbits
AT agrogiannisg pharmacokineticsofintravitrealbevacizumabavastinampreginrabbits
AT pantopouloua pharmacokineticsofintravitrealbevacizumabavastinampreginrabbits
AT theocharisse pharmacokineticsofintravitrealbevacizumabavastinampreginrabbits
AT baltatziss pharmacokineticsofintravitrealbevacizumabavastinampreginrabbits
AT patsourise pharmacokineticsofintravitrealbevacizumabavastinampreginrabbits
AT perreadn pharmacokineticsofintravitrealbevacizumabavastinampreginrabbits
_version_ 1718403157453701120

Ejemplares similares